TrialJournal of hepatology2025

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

George Lau et al.PubMed ↗Publisher ↗

No numbers read from the abstract.